Sanofi (NYSE: SNY) reported Q4 EPS of EUR1.06, EUR0.09 worse than the analyst estimate of EUR1.15. Revenue for the quarter came in at EUR8.69 billion versus the consensus estimate of EUR8.67 billion.

Sanofi expects 2018 business EPS(1) to grow between 2% and 5%(7) at CER, including the anticipated contribution from the recently announced acquisitions, barring unforeseen major adverse events. Applying the average December 2017 exchange rates, the currency impact on 2018 business EPS is estimated to be -3% to -4%.

For earnings history and earnings-related data on Sanofi (SNY) click here.